Eric Bansal, MD
Interventional Cardiology · Los Angeles, CANPI 1689945776
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,147 of the $9,562 with a category attached, or 85.2%. 30 manufacturers reported payments, led by Boston Scientific at 27.5% of the total. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 268 payments — averaging $35.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abiomed$2K
- Edwards Lifesciences$1K
- Medtronic$889
- Shockwave Medical, Inc$841
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$563
- plus $2K from 24 others
What the payments were for
- Grants$1001%
- Travel & lodging$1,30114%
- Food & beverage$8,14785%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $2,626 |
| Abiomed | 31 | $1,732 |
| Edwards Lifesciences | 25 | $1,175 |
| Medtronic(2 entities) | 34 | $889 |
| Shockwave Medical, Inc | 36 | $841 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $563 |
| Abbott | 7 | $204 |
| E.r. Squibb & Sons, L.L.C. | 8 | $191 |
| Chiesi USA, Inc. | 10 | $177 |
| Novartis | 10 | $177 |
| Amgen | 10 | $175 |
| AbbVie | 1 | $97 |
| AstraZeneca | 4 | $80 |
| Lantheus Medical Imaging, Inc. | 3 | $69 |
| Merck | 3 | $68 |
| Veryan Medical Incorporated | 1 | $55 |
| Boehringer Ingelheim | 2 | $52 |
| Cook Medical LLC | 2 | $50 |
| Livanova USA, Inc. | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $46 |
| Pfizer | 2 | $39 |
| Irhythm Technologies, Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $30 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Cardiva Medical, Inc. | 1 | $23 |
| GSK | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,562 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 82 | $62,225 |
| JardianceEmpagliflozin | 71 | $46,934 |
| EliquisApixaban | 71 | $45,531 |
| BrilintaTicagrelor | 48 | $26,894 |
| FarxigaDapagliflozin Propanediol | 14 | $7,609 |
| Atorvastatin Calcium | 260 | $1,735 |
| Nifedipine ErNifedipine | 29 | $1,321 |
| Metoprolol Succinate | 73 | $890 |
| ClopidogrelClopidogrel Bisulfate | 112 | $580 |
| Carvedilol | 121 | $544 |
| Labetalol Hcl | 16 | $479 |
| Hydralazine Hcl | 16 | $424 |
| Bumetanide | 12 | $393 |
| Ezetimibe | 15 | $379 |
| Pantoprazole Sodium | 74 | $327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $177 | $62,22582 claims |
| Boehringer IngelheimJardiance | $52 | $46,93471 claims |
| PfizerEliquis | $39 | $45,53171 claims |
| AstraZenecaBrilinta, Farxiga | $80 | $34,50362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Los Angeles
- Evan ZahnLos Angeles$632K
- Steven BursteinLos Angeles$352K
- Jubin JosephLos Angeles$217K
- Ali NsairLos Angeles$162K
- Ray MatthewsLos Angeles$159K
- Daniel AsemotaLos Angeles$155K
- Christina EconomidesLos Angeles$150K
- Aakriti GuptaLos Angeles$139K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.